ZY19489: A potential single dose cure for Malaria recognized in the WHO Malaria Report amongst the most important malaria treatments in development

Malaria remains a major health issue, with millions of cases and thousands of deaths annually, especially among children in endemic regions. Zintrodiazine is being developed in collaboration with Medicines for Malaria Venture (MMV), a global partnership focused on innovative anti-malarial solutions. The molecule is being developed as a strategic initiative to combat malaria, particularly in response to the growing challenge of drug-resistant strains of Plasmodium falciparum and Plasmodium vivax.

It is being developed to offer an alternative to current front-line drugs, addressing resistance to artemisinin-based combination therapies (ACTs). During the year, Zintrodiazine completed Phase II clinical trials for P. falciparum strain and P. vivax strain. Protocol for Phase III clinical trials was also submitted to DCGI. On the global development front, it is being positioned as a combination treatment with Ferroquine for malaria in the endemic regions with heavy disease burden.

The USFDA has granted an Orphan Drug Designation (ODD) to Zintrodiazine, recognizing its potential to treat a serious condition with limited treatment options in the US.